Nationally Recognized FDA Partner Bethany J. Hills Joins Morrison & Foerster in New York
Welcome to Mofo Life Sciences
MoFo Life Sciences shares timely legal and business insights and in-depth analyses on trends and the complex technologies at the heart of the global pharmaceutical, biotechnology, diagnostics, medical devices, digital health, and AgTech fields.
- Ms. Hills brings a full-service FDA practice to the firm rounding out its market-leading Life Sciences Group Morrison & Foerster, a leading global law firm, is pleased to announce that Bethany J. Hills has joined the firm in the New York office as a... ›
Patent Term Adjustment: A Post-Supernus Update from the Patent and Trademark Office
By: Karen G Potter Ph.D.
On May 9, the United States Patent and Trademark Office (“PTO”) published a notice in the Federal Register that it is modifying its patent term adjustment (“PTA”) procedures in view of the Federal Circuit’s decision in Supernus Pharmaceuticals v. Iancu .[1] Under the PTO... ›Supreme Court Decides Prescription Drug Preemption Case in Favor of Drug Manufacturer
By: Erin M. Bosman and Julie Y. Park
The United States Supreme Court finally clarified its 11-year-old “clear evidence” standard for pharmaceutical preemption. In its much-anticipated opinion delivered by Justice Breyer, the Court unanimously reversed the Third Circuit’s holding that questions of pharmaceutical preemption should be decided by juries. Merck Sharp &... ›Artificial Intelligence and Machine Learning: Real-world applications
With Artificial Intelligence (AI) and Machine Learning (ML) rapidly becoming significant players in multiple areas of science and technology, it came as no surprise to witness a full house for Athena’s program “Taking Artificial Intelligence (AI) and Machine Learning (ML) from Concept to Application,”... ›The Diagnostics Dilemma: Securing and Protecting Diagnostic-Based Claims
By: Karen G Potter Ph.D.
While many life sciences companies are built on platforms involving the development of diagnostic products and methods that underlie personalized medicine allowing treatment that is customized to a patient’s unique biology, the U.S. Supreme Court dealt a blow to the industry with its decision... ›AI And Life Sciences – A New Wave Of Innovation
By: Jean Nguyen Ph.D.
Artificial intelligence and life sciences – the combination of the two is creating a new wave of innovation. With AI, we now have the power to analyze massive amounts of data for drug discovery, medical diagnosis, biotechnology, clinical trials, personalized medicine, electronic health records,... ›Congress releases bipartisan draft bill to repair the law on patent eligibility
By: Karen G Potter Ph.D. and Jeffrey W. Schmidt Ph.D.
On May 22, 2019, members of Congress made available for public comment a one-page draft of a bill that aims to rewrite the patent eligibility provisions of the Patent Act to address the muddled jurisprudence spawned by the Supreme Court cases of Mayo Collaborative... ›Manufacturing Waiver Weakens SPC Protection in Europe
By: Wolfgang Schönig
On May 14, 2019, the Council of the European Union adopted the amending Regulation (EC) No. 469/2009 , effectively exempting certain manufacturing activities in the EU from the scope of Supplementary Protection Certificates that have not yet been granted (“New SPC Regulation”). The New SPC Regulation will enter... ›Second Annual Blockchain Healthcare Summit
By: Spencer D. Klein, Jonathan Bockman and Kristen J. Mathews
The industry leading Blockchain Healthcare Summit is returning to New York City on June 13. Now in its second year, the Summit offers a research-based program addressing opportunities to incorporate blockchain technology to increase efficiency, transparency, and security for the healthcare industry. Through a... ›An Easier Road to a Hong Kong Listing for Biotech Companies
By: Vivian Yiu, Janet Xiao Ph.D. and Jie Zhou Ph.D.
In June 2017, the Hong Kong Stock Exchange (“HKEx”) initiated a holistic review of the Hong Kong listing regime to enhance its overall competitiveness against other major global listing venues, in particular to attract companies from emerging and innovative sectors. During this review, the... ›